Allos Therapeutics to Present at SG Cowen's Healthcare Conference

Allos Therapeutics to Present at SG Cowen's Healthcare Conference



WESTMINSTER, Colo., March 11  /PRNewswire-FirstCall/ -- Allos Therapeutics,
Inc. (NASDAQ:ALTH) today announced that the Company will participate in SG
Cowen's 2005 Healthcare Conference, to be held March 14 - 17 in Boston, MA.
Michael E. Hart, the Company's President and Chief Executive Officer will give
a 40-minute corporate overview on Wednesday, March 16 at 2:20 PM ET.

The presentation will be webcast live and may be accessed by visiting the Allos
website at http://www.allos.com/.  A replay of the webcast will also be
available on the company's website until Friday, April 15, 2005.

About Allos Therapeutics, Inc.

Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing
and commercializing innovative drugs for improving cancer treatments.  The
company's lead clinical candidate, EFAPROXYN(TM) (efaproxiral), is a synthetic
small molecule that has the potential to sensitize hypoxic (oxygen deprived)
tumor tissues and enhance the efficacy of standard radiation therapy.  In
addition, Allos is developing PDX (pralatrexate), a novel small molecule
cytotoxic injectable antifolate (DHFR inhibitor) intended to treat non-small
cell lung cancer and non-Hodgkin's lymphoma, as well as RH1, a targeted
cytotoxic prodrug under investigation in patients with advanced solid tumors. 
For more information, please visit the company's web site at:
http://www.allos.com/.

Safe Harbor Statement

This press release and the anticipated presentation contain forward- looking
statements that involve significant risks and uncertainties, including those
discussed in this release, those to be discussed in the presentation and others
that can be found in the "Risk Factors" section of the Company's Form 10-K/A
for the year ended December 31, 2003 and in the Company's periodic reports on
Form 10-Q and Form 8-K.  The Company does not undertake any obligation to
update any forward-looking statements contained in this document or the
anticipated presentation as a result of new information, future events or
otherwise.  The Company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release or the presentation.
 No forward-looking statement can be guaranteed and actual events and results
may differ materially from those projected. 

DATASOURCE: Allos Therapeutics, Inc.



CONTACT:  Jennifer Neiman, Manager, Corporate Communications of Allos

Therapeutics, [phone], 



Web site:  http://www.allos.com/ 

Copyright